Premier Biomedical, Inc., a biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancer, traumatic brain injury, Alzheimer’s disease, and other conditions, announced today that it is outlining a protocol for the Institutional Review Board to guide the Company’s clinical trial of Feldetrex™, a revolutionary new drug addressing pain treatment. The Company expects to be able to submit the protocol in mid-August. A second clinical trial of the Company’s core technology to “physically remove the pathophysiologic basis of disease” will follow.
The Feldetrex™ trial is aimed at treating patients suffering from fibromyalgia, MS, and neuropathy. This will be a double-blind study, in which the patient population will be tested via a Sequential Series of Tests, or via a Cross-Over Test. One of four treatments will be given to patients: a placebo, Lyrica®, Feldetrex™ or a Lyrica-Feldetrex™ blend. Dr. Roxanna Delgado, part of the US Army-based team administering the clinical trial, will conduct both clinical trials at the William Beaumont Army Medical Center (WBAMC). She will be supported by the medical experimentation statistical service department at the University of Texas, El Paso, under the guidance of Dr. Robert Kirken, UTEP’s principal investigator. Feldetrex ™ was recently allowed 4 claims by the US Patent Office.
William Hartman, President and CEO of Premier Biomedical said, “We are looking forward to working with the Army in these trials. We believe that both of our technologies, Feldetrex™ and the removal of the pathophysiologic basis of disease, will be of immense benefit to patients. Given the special situation of our wounded heroes, I am particularly happy that we have the chance to work with the Army to bring some relief to the patriots who are still suffering on our behalf.”
It is in Premier Biomedical’s plans to conduct another study on its core technology in order to physically remove the pathophysiologic basis of disease™. The Company specifically seeks to demonstrate that the malevolent molecular compounds that cause clinical depression leading to suicide/homicide ideation can be removed. 20 claims involving this basic technology sustaining Premier’s on-going research of new treatments for most debilitating diseases were recently allowed by the US Patent Office.
Mr. Hartman went on to explain that, “By removing these compounds from the cerebral spinal fluid of individual soldiers suffering from traumatic brain injury and/or PTSD we are removing the very thing that causes their illnesses. We have arrived at this point because we already successfully removed these same malevolent particles from pooled CSF furnished through the WBAMC Army-based team. This is a revolutionary approach to the problem, and we are very hopeful that this upcoming trial will represent another step forward in the treatment of brain injuries and PTSD.”
This second test will take place at the WBAMC as well, and it will right after the first clinical study is complete. The same Army-based team will be administering it. The protocol will be drafted for IRB review as the first study progresses.
Premier Biomedical, Inc. is a research company dedicated to discovering and developing medical treatments covering a wide range of diseases. It collaborates with the University of Texas at El Paso and the US Department of Defense. The company initially targeted the treatment of Alzheimer’s disease, Traumatic Brain Injury, and Cancer. It has licensed the technology conducting to multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has celebrate partnerships with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company’s R&D is headquartered in El Paso, TX with business offices in Western Pennsylvania. The Company’s common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol “BIEI.”